Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860697 | 0.83 | GSK3B (0.42) | GPR35GSK3BDAOKDM4EALDH1A1 | |
| SCHEMBL5104631 | 0.82 | PKM (0.52) | GPR35DAOKDM4EALDH1A1MEN1 | |
| SCHEMBL31073398 | 0.81 | GSK3B (0.41) | GPR35GSK3BDAOKDM4EALDH1A1 | |
| SCHEMBL27602779 | 0.78 | GSK3B (0.47) | GSK3BKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL2730725 | 0.78 | MAPT (0.44) | GSK3BKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL15878596 | 0.77 | GSK3B (0.61) | GPR35GSK3BDAOPKMRXFP1 | |
| SCHEMBL31223143 | 0.76 | GSK3B (0.44) | GPR35GSK3BDAOKDM4EALDH1A1 | |
| SCHEMBL1974281 | 0.76 | GSK3B (0.44) | GPR35GSK3BDAOKDM4EALDH1A1 | |
| SCHEMBL3093344 | 0.76 | DAO (0.65) | GPR35DAOKDM4EALDH1A1MEN1 | |
| SCHEMBL1437636 | 0.75 | GSK3B (0.44) | GPR35GSK3BDAOPKMRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-5639749-A | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0773943-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5625061-A | GRAFT=GLYCINAMIDE RIBONCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5610319-A | Compound useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5594139-A | FROM 5-HAL-2,6-DIAMINO-3H-4-OXOPYRIMIDINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996003406-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003407-A1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | GPR35 2376/4885GSK3B 789/4885DAO 449/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | GPR35 2376/4885GSK3B 789/4885DAO 449/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | GPR35 3138/4885GSK3B 1862/4885DAO 2771/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | GPR35 1130/4885GSK3B 564/4885DAO 2854/4885 |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | GPR35 2376/4885GSK3B 789/4885DAO 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.